{"entity":{"id":"nct07647328","kind":"trial","name":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer","aka":["SERAFA-1"],"tldr":"A phase 3 trial of Camizestrant and Ribociclib in HR-positive / HER2-negative breast cancer, run by AstraZeneca, now recruiting.","summary":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer is a phase 3 interventional study registered as NCT07647328 by AstraZeneca, with 150 participants planned, started 2026-06-15 and due to reach its primary completion in 2029-02-28. Interventions recorded: Camizestrant and Ribociclib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07647328","url":"https://clinicaltrials.gov/study/NCT07647328"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["cdk46-inhibitor","endocrine-therapy"],"targets":[],"drugs":["camizestrant","ribociclib"],"companies":["astrazeneca","icon-plc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07647328","phase":"3","setting":"SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients","sponsor":"AstraZeneca","participation":[{"nct":"NCT07647328","source":"https://clinicaltrials.gov/study/NCT07647328","fetchedAt":"2026-10-07T16:55:52.872Z","studySha256":"6b6651baa7d84a28f8c11b09db95d48199fe647d8ea1c28844b8a4e5c1560ebb","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-08","leadSponsor":"AstraZeneca","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":150,"enrolmentType":"ESTIMATED","siteCount":89,"recruitingSiteCount":2,"countries":["France","Germany","Italy","Poland","South Korea","Spain","Switzerland","United Arab Emirates","United States"]}],"started":"2026-06-15","startedType":"actual","enrolled":150,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07647328/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/"},{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"drug":[{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"icon-plc","kind":"company","name":"ICON plc","route":"/companies/icon-plc/"}]}}